Literature DB >> 9020321

Tacrolimus rescue therapy for renal allograft rejection--five-year experience.

M L Jordan1, R Naraghi, R Shapiro, D Smith, C A Vivas, V P Scantlebury, H A Gritsch, J McCauley, P Randhawa, A J Demetris, J McMichael, J J Fung, T E Starzl.   

Abstract

Over the 5 year period from 7/14/1989 until 5/24/1994, we have attempted graft salvage with tacrolimus conversion in a total of 169 patients (median age 33 years, range 2-75 years) with ongoing rejection on baseline CsA immunosuppression after failure of high dose corticosteroids and/or antilymphocyte preparations to reverse rejection. The indications for conversion to tacrolimus were ongoing, biopsy confirmed rejection in all patients. The median interval to tacrolimus conversion was 2 months (range 2 days to 55 months; mean 4.3+/-2.6 months) after transplantation. All patients had failed high dose corticosteroid therapy and 144 (85%) of the 169 patients had received at least one course of an antilymphocyte preparation plus high dose corticosteroid therapy prior to conversion. Twenty-eight patients (17%) were dialysis-dependent at the time of conversion owing to the severity of rejection. With a mean follow-up of 30.0+/-2.4 months (median 36.5 months, range 12-62 months), 125 of 169 patients (74%) have been successfully rescued and still have functioning grafts with a mean serum creatinine (SCR) of 2.3+/-1.1 mg/dl. Of the 144 patients previously treated with antilymphocyte preparations, 117 (81%) were salvaged. Of the 28 patients on dialysis at the time of conversion to tacrolimus, 13 (46%) continue to have functioning grafts (mean SCR 2.15+/-0.37 mg/dl) at a mean follow-up of 37.3+/-16.7 months. In the 125 patients salvaged, prednisone doses have been lowered from 28.0+/-9.0 mg/d (median 32, range 4-60 mg/d) preconversion to 8.5+/-4.1 mg/d (median 12 mg/d, range 2.5-20 mg/d) postconversion. Twenty-eight patients (22.4%) are currently receiving no steroids. This 5 year experience demonstrates that tacrolimus has sustained efficacy as a rescue agent for ongoing renal allograft rejection. Based on these data, we recommend that tacrolimus be used as an alternative to the conventional drugs used for antirejection therapy in renal transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9020321      PMCID: PMC2982701          DOI: 10.1097/00007890-199701270-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C W Jensen; V Scantlebury; J Fung; A Tzakis; J McCauley; A Jain; J Demetrius; P Randhawa
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  A whole blood FK 506 assay for the IMx analyzer.

Authors:  F C Grenier; J Luczkiw; M Bergmann; S Lunetta; M Morrison; D Blonski; K Shoemaker; M Kobayashi
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

4.  Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.

Authors:  D J Frey; A J Matas; K J Gillingham; D Canafax; W D Payne; D L Dunn; D E Sutherland; J S Najarian
Journal:  Transplantation       Date:  1992-07       Impact factor: 4.939

5.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

6.  Sequential antilymphoblast globulin and cyclosporine for renal transplantation.

Authors:  B G Sommer; M Henry; R M Ferguson
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

7.  RS-61443--a phase I clinical trial and pilot rescue study.

Authors:  H W Sollinger; M H Deierhoi; F O Belzer; A G Diethelm; R S Kauffman
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

8.  Analyses of the UNOS Scientific Renal Transplant Registry at three years--early events affecting transplant success.

Authors:  J M Cecka; Y W Cho; P I Terasaki
Journal:  Transplantation       Date:  1992-01       Impact factor: 4.939

9.  RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection.

Authors:  H W Sollinger; F O Belzer; M H Deierhoi; A G Diethelm; T A Gonwa; R S Kauffman; G B Klintmalm; S V McDiarmid; J Roberts; J T Rosenthal
Journal:  Ann Surg       Date:  1992-10       Impact factor: 12.969

10.  Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity.

Authors:  S Hariharan; R Munda; T Cavallo; A M Demmy; T J Schroeder; J W Alexander; M R First
Journal:  Transplantation       Date:  1996-04-27       Impact factor: 4.939

View more
  7 in total

1.  Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow-up.

Authors:  M L Jordan; R Shapiro; C Vivas; V Scantlebury; J McCauley; J McMichael; P Randhawa; A Demetris; J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1999-11       Impact factor: 1.066

2.  Tacrolimus for rescue of refractory renal allograft rejection.

Authors:  M L Jordan; R Naraghi; R Shapiro; D Smith; C A Vivas; V P Scantlebury; H A Gritsch; J McCauley; P Randhawa; A J Demetris; J McMichael; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

3.  Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature.

Authors:  R Shapiro; V P Scantlebury; M L Jordan; C Vivas; H A Gritsch; J McCauley; J J Fung; T R Hakala; R L Simmons; T E Starzl
Journal:  Transplant Proc       Date:  1997-09       Impact factor: 1.066

4.  Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression.

Authors:  M L Jordan; P Chakrabarti; P Luke; R Shapiro; C A Vivas; V P Scantlebury; J J Fung; T E Starzl; R J Corry
Journal:  Transplantation       Date:  2000-01-27       Impact factor: 4.939

5.  Long-term results of pancreas transplantation under tacrolius immunosuppression.

Authors:  M L Jordan; R Shapiro; H A Gritsch; F Egidi; A Khanna; C A Vivas; V P Scantlebury; J J Fung; T E Starzl; R J Corry
Journal:  Transplantation       Date:  1999-01-27       Impact factor: 4.939

Review 6.  Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

Authors:  C M Spencer; K L Goa; J C Gillis
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 7.  Prevention of transplant rejection: current treatment guidelines and future developments.

Authors:  N Perico; G Remuzzi
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.